Takeda Pharmaceutical Co. (TAK) is earning recognition as a strong buy recently due to its value proposition for investors. Despite a downturn in recent weeks, many analysts anticipate a possible turnaround for TAK. Apollon Wealth Management LLC and GAMMA Investing LLC have been adding TAK to their portfolios, and the company remains largely owned by retail investors. However, there are concerns currently about the operating profit for FY23 alongside a slashing of full-year profit forecast due to drug pipeline impairments. A noteworthy event is TAK’s achievement of FDA approval for its rare blood disorder therapy, signifying progress in its drug pipeline. Despite these successes, the stock experienced a 12-month low at $12.77, likely influenced by projected profit slides and heightened competition. From a broader perspective, TAK shareholders have seen an 8.8% CAGR over the past three years. TAK's hire of Molly Rabinovitz Stock as its US unit storyteller, and HilleVax's $200M IPO for a vaccine test involving Takeda, are other notable updates.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Fri, 17 May 2024 23:20:16 GMT -
Rating 3
- Innovation -5
- Information 7
- Rumor -4
